Bristol Myers Squibb shared on LinkedIn:
“Today, we announced positive topline results from a Phase 3 trial evaluating our novel oral combination therapy in patients with relapsed or refractory multiple myeloma.
These results reinforce the clinical value of this innovative treatment option for people living with MM. We extend our deepest gratitude to the trial participants, caregivers and researchers whose dedication continues to help us redefine what’s possible in blood cancer care.”
Read the full article here.
You may also be interested in: BMS Reports Iberdomide Combination Reduces Risk of Progression or Death by 51% in Relapsed or Refractory Multiple Myeloma
